

**REGION I EMERGENCY MEDICAL SERVICES
STANDING MEDICAL ORDERS
EMT – Paramedic**

SMO: Significant Nausea / Vomiting treating with Ondansetron (Zofran)

Overview: Nausea / vomiting are a side effect of many medical and traumatic emergencies. Medications to control nausea / vomiting are in addition to the standard treatment of those emergencies.

INFORMATION NEEDED

- Duration of the nausea / vomiting
- Previous episodes of nausea / vomiting
- Circumstances of occurrence (e.g. patient's position before the event, severe pain, emotional stress)
- Other associated symptoms

OBJECTIVE FINDINGS

- Vital signs (especially pulse rate, quality, regularity)
- Other information as listed above

Indications

- Nausea
- Vomiting
- Motion sickness

Contraindications

- Hypersensitivity to Ondansetron (Zofran)

TREATMENT

- Initiate contact; reassure, and explain procedures.
- Assess and secure the patient's airway and provide oxygen per the airway, oxygen and ventilation protocol.
- Perform patient assessment, obtain vital signs and begin cardiac monitoring.
- Initiate IV access with a saline lock or 0.9 % normal saline KVO
- Check patient history for record of allergies, sensitivity to ondansetron, granisetron, palonosetron, or dolasetron.
- Administer Ondansetron (Zofran)
 - Adults: 4 mg slow IV over 2 minutes or IM
 - Pediatrics > 40 kg (88 lbs): 4 mg slow IV over 2 minutes or IM
 - Pediatrics ≤ 40 kg (88 lbs): 0.1 mg/kg slow IV over 2 minutes or IM

11/07

Reviewed: Revised:
EMS/ Region1 SMOs

Documentation of adherence to protocol:

- Dose and time Ondansetron (Zofran) administered
- Vitals before and after administration of Ondansetron (Zofran)

Medical Control Contact Criteria

- Contact Medical Control if any question exists as to whether or not this protocol should apply
- Contact Medical Control if additional doses are needed

PRECAUTIONS AND COMMENTS

- Side effects of Ondansetron (Zofran) are drowsiness, dizziness, hypotension, flushing, musculoskeletal pain, cardiovascular disturbances, headache, and redness at injection site.

11/07

Reviewed: Revised:
EMS/ Region1 SMOs